BioTuesdays

Tag - Brookline Capital Markets

X4 Pharma

Brookline starts X4 Pharma at buy; PT $21

Brookline Capital Markets launched coverage of X4 Pharmaceuticals (NASDAQ:XFOR) with a “buy” rating and $21 price target. The stock closed at $6.10 on Dec. 16. X4 Pharmaceuticals is focused on diseases resulting from...

Syros-Logo

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

electroCore Logo

Brookline starts electroCore at buy; PT $5

Brookline Capital Markets launched coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and price target of $5. The stock closed at $1.57 on Oct. 22. electroCore is a bioelectronic medicine company whose lead...

CTIBiopharmaLogo

Brookline starts CTI Biopharma at buy; PT $7

Brookline Capital Markets initiated coverage of CTI BioPharma (NASDAQ:CTIC) with a “buy” rating and $7 price target. The stock closed at $3.34 on Oct. 22. CTI is focused on novel targeted therapies for hematologic...

Brookline starts MEI Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and price target of $10. The stock closed at $3.08 on Oct. 9. Analyst Leah Rush Cann writes that MEI Pharma is developing...

Constellation Logo

Brookline starts Constellation Pharma at buy; PT $33

Brookline Capital Markets initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $33 price target. The stock closed at $21 on Sept 2. Constellation is using epigenetics to address...

Brookline Logo

Brookline boosts life sciences equity research

Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team.  With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...

Cyclacel Pharmaceuticals

Brookline starts Cyclacel Pharma at buy; PT $22

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...

Biocept Logo

Brookline starts Biocept at buy; PT $2.06

Brookline Capital Markets initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and price target of $2.06. The stock closed at 44 cents on May 13. Biocept is a molecular oncology diagnostics company that...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.